A Study of Subcutaneously Administered Tocilizumab in Patients With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This open-label randomized 2arm study will investigate the pharmacokinetics,
pharmacodynamics, efficacy and safety of subcutaneously administered tocilizumab in patients
with rheumatoid arthritis who have shown an inadequate response to methotrexate. Patients
will be randomized to receive tocilizumab 162 mg sc either weekly or every other week, in
combination with methotrexate, for 12 weeks. Assessments will be made at regular intervals
during treatment and on the 3 weeks of follow-up.Target sample size is < 50 individuals.